NCT02289079

Brief Summary

The purpose of the study is to compare pain control after robotic hysterectomy surgery using either liposomal bupivacaine or Bupivacaine when injected during a transversus abdominis plane (TAP) block. Robotic hysterectomy is when a patient is electively having robotic assisted removal of one's uterus. Both medications liposomal bupivacaine and Bupivacaine are standard of care in these types of surgeries.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at P25-P50 for phase_4

Timeline
Completed

Started Jun 2013

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2013

Completed
1.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2014

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2014

Completed
29 days until next milestone

First Submitted

Initial submission to the registry

October 30, 2014

Completed
14 days until next milestone

First Posted

Study publicly available on registry

November 13, 2014

Completed
1.2 years until next milestone

Results Posted

Study results publicly available

January 18, 2016

Completed
Last Updated

May 10, 2023

Status Verified

May 1, 2023

Enrollment Period

1.3 years

First QC Date

October 30, 2014

Results QC Date

December 11, 2015

Last Update Submit

May 8, 2023

Conditions

Outcome Measures

Primary Outcomes (1)

  • Post Operative Opioid Use

    To determine if liposomal bupivacaine provides decreased narcotic use when compared to bupivacaine when injected in a TAP block

    0-72 hours after injection

Secondary Outcomes (3)

  • Numerical Rating Scale

    48-72 hours

  • Post Operative Length of Stay

    up to 30 days after surgery

  • Patient Satisfaction as Assessed Via Patient Survey

    assessed at 72 hours after injection

Study Arms (2)

liposomal bupivacaine TAP

EXPERIMENTAL

these patients receive a subcostal TAP with liposomal bupivacaine

Drug: liposomal bupivacaine

bupivacaine TAP

ACTIVE COMPARATOR

These patients receive a subcostal TAP with bupivacaine

Drug: Bupivacaine

Interventions

bupivacaine TAP
liposomal bupivacaine TAP

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • those who present for elective robotic assisted hysterectomy

You may not qualify if:

  • non english speaking
  • chronic pain
  • on opioids greater than 1 weeks
  • chronic anticoagulation
  • allergy to local anesthetics
  • use of spinal or epidural for surgery
  • lack of patient cooperation
  • contraindication to regional anesthesia

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (1)

  • Hutchins J, Delaney D, Vogel RI, Ghebre RG, Downs LS Jr, Carson L, Mullany S, Teoh D, Geller MA. Ultrasound guided subcostal transversus abdominis plane (TAP) infiltration with liposomal bupivacaine for patients undergoing robotic assisted hysterectomy: A prospective randomized controlled study. Gynecol Oncol. 2015 Sep;138(3):609-13. doi: 10.1016/j.ygyno.2015.06.008. Epub 2015 Jun 6.

MeSH Terms

Conditions

Acute Pain

Interventions

Bupivacaine

Condition Hierarchy (Ancestors)

PainNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

AnilidesAmidesOrganic ChemicalsAniline CompoundsAmines

Results Point of Contact

Title
Dr. Jacob Hutchins
Organization
University of MInnesota

Publication Agreements

PI is Sponsor Employee
Yes

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 30, 2014

First Posted

November 13, 2014

Study Start

June 1, 2013

Primary Completion

October 1, 2014

Study Completion

October 1, 2014

Last Updated

May 10, 2023

Results First Posted

January 18, 2016

Record last verified: 2023-05